Report Detail
Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2025
- RnM3541909 |
- 22 May, 2020 |
- Global |
- 108 Pages |
- QYResearch |
- Pharma & Healthcare
This report covers market size and forecasts of Circulating Tumor Cell Diagnostics, including the following market information:
Global Circulating Tumor Cell Diagnostics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Circulating Tumor Cell Diagnostics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Circulating Tumor Cell Diagnostics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Circulating Tumor Cell Diagnostics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc., Fluxion Biosciences Inc., ScreenCell, Silicon Biosystems, Sysmex Corporation, Greiner Bio-One GmbH, AdnaGen AG, Apocell Inc, Biocep Ltd, Canopus Bioscience Ltd, Creatv Microtech Inc, Ikonisys Inc, IV Diagnostics Inc, Miltenyi Biotech GmbH, Nanostring Technologies Inc, Rarecells Diagnostics., Vitatex Inc, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
CTC Enrichment
CTC Detection
CTC Analysis
Based on the Application:
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Circulating Tumor Cell Diagnostics Quarterly Market Size Analysis
- 2.1 Circulating Tumor Cell Diagnostics Business Impact Assessment - COVID-19
- 2.1.1 Global Circulating Tumor Cell Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Circulating Tumor Cell Diagnostics Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 By Players, Global Circulating Tumor Cell Diagnostics Quarterly Market Size, 2019 VS 2020
- 3.2 By Players, Circulating Tumor Cell Diagnostics Headquarters and Area Served
- 3.3 Date of Key Players Enter into Circulating Tumor Cell Diagnostics Market
- 3.4 Key Players Circulating Tumor Cell Diagnostics Product Offered
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Circulating Tumor Cell Diagnostics Segments, By Type
- 4.1 Introduction
- 1.4.1 CTC Enrichment
- 1.4.2 CTC Detection
- 1.4.3 CTC Analysis
- 4.2 By Type, Global Circulating Tumor Cell Diagnostics Market Size, 2019-2021
5 Impact of Covid-19 on Circulating Tumor Cell Diagnostics Segments, By Application
- 5.1 Overview
- 5.5.1 Tumorigenesis research
- 5.5.2 EMT biomarkers development
- 5.5.3 Cancer stem cell research
- 5.5.4 Others
- 5.2 By Application, Global Circulating Tumor Cell Diagnostics Market Size, 2019-2021
- 5.2.1 By Application, Global Circulating Tumor Cell Diagnostics Market Size by Application, 2019-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Janssen Diagnostics
- 7.1.1 Janssen Diagnostics Business Overview
- 7.1.2 Janssen Diagnostics Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Introduction
- 7.1.4 Janssen Diagnostics Response to COVID-19 and Related Developments
- 7.2 Advanced Cell Diagnostics
- 7.2.1 Advanced Cell Diagnostics Business Overview
- 7.2.2 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Introduction
- 7.2.4 Advanced Cell Diagnostics Response to COVID-19 and Related Developments
- 7.3 Aviva Biosciences
- 7.3.1 Aviva Biosciences Business Overview
- 7.3.2 Aviva Biosciences Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Product Introduction
- 7.3.4 Aviva Biosciences Response to COVID-19 and Related Developments
- 7.4 Biocept Inc
- 7.4.1 Biocept Inc Business Overview
- 7.4.2 Biocept Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.4.4 Biocept Inc Response to COVID-19 and Related Developments
- 7.5 Biofluidica Inc.
- 7.5.1 Biofluidica Inc. Business Overview
- 7.5.2 Biofluidica Inc. Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Product Introduction
- 7.5.4 Biofluidica Inc. Response to COVID-19 and Related Developments
- 7.6 CellTraffix Inc.
- 7.6.1 CellTraffix Inc. Business Overview
- 7.6.2 CellTraffix Inc. Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Introduction
- 7.6.4 CellTraffix Inc. Response to COVID-19 and Related Developments
- 7.7 Clearbridge BioMedics Pte Ltd
- 7.7.1 Clearbridge BioMedics Pte Ltd Business Overview
- 7.7.2 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Introduction
- 7.7.4 Clearbridge BioMedics Pte Ltd Response to COVID-19 and Related Developments
- 7.8 Epic Sciences Inc.
- 7.8.1 Epic Sciences Inc. Business Overview
- 7.8.2 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Introduction
- 7.8.4 Epic Sciences Inc. Response to COVID-19 and Related Developments
- 7.9 Fluxion Biosciences Inc.
- 7.9.1 Fluxion Biosciences Inc. Business Overview
- 7.9.2 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Introduction
- 7.9.4 Fluxion Biosciences Inc. Response to COVID-19 and Related Developments
- 7.10 ScreenCell
- 7.10.1 ScreenCell Business Overview
- 7.10.2 ScreenCell Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.10.3 ScreenCell Circulating Tumor Cell Diagnostics Product Introduction
- 7.10.4 ScreenCell Response to COVID-19 and Related Developments
- 7.11 Silicon Biosystems
- 7.11.1 Silicon Biosystems Business Overview
- 7.11.2 Silicon Biosystems Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Product Introduction
- 7.11.4 Silicon Biosystems Response to COVID-19 and Related Developments
- 7.12 Sysmex Corporation
- 7.12.1 Sysmex Corporation Business Overview
- 7.12.2 Sysmex Corporation Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Product Introduction
- 7.12.4 Sysmex Corporation Response to COVID-19 and Related Developments
- 7.13 Greiner Bio-One GmbH
- 7.13.1 Greiner Bio-One GmbH Business Overview
- 7.13.2 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Introduction
- 7.13.4 Greiner Bio-One GmbH Response to COVID-19 and Related Developments
- 7.14 AdnaGen AG
- 7.14.1 AdnaGen AG Business Overview
- 7.14.2 AdnaGen AG Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Product Introduction
- 7.14.4 AdnaGen AG Response to COVID-19 and Related Developments
- 7.15 Apocell Inc
- 7.15.1 Apocell Inc Business Overview
- 7.15.2 Apocell Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.15.4 Apocell Inc Response to COVID-19 and Related Developments
- 7.16 Biocep Ltd
- 7.16.1 Biocep Ltd Business Overview
- 7.16.2 Biocep Ltd Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Product Introduction
- 7.16.4 Biocep Ltd Response to COVID-19 and Related Developments
- 7.17 Canopus Bioscience Ltd
- 7.17.1 Canopus Bioscience Ltd Business Overview
- 7.17.2 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Introduction
- 7.17.4 Canopus Bioscience Ltd Response to COVID-19 and Related Developments
- 7.18 Creatv Microtech Inc
- 7.18.1 Creatv Microtech Inc Business Overview
- 7.18.2 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.18.4 Creatv Microtech Inc Response to COVID-19 and Related Developments
- 7.19 Ikonisys Inc
- 7.19.1 Ikonisys Inc Business Overview
- 7.19.2 Ikonisys Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.19.4 Ikonisys Inc Response to COVID-19 and Related Developments
- 7.20 IV Diagnostics Inc
- 7.20.1 IV Diagnostics Inc Business Overview
- 7.20.2 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.20.4 IV Diagnostics Inc Response to COVID-19 and Related Developments
- 7.21 Miltenyi Biotech GmbH
- 7.21.1 Miltenyi Biotech GmbH Business Overview
- 7.21.2 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Introduction
- 7.21.4 Miltenyi Biotech GmbH Response to COVID-19 and Related Developments
- 7.22 Nanostring Technologies Inc
- 7.22.1 Nanostring Technologies Inc Business Overview
- 7.22.2 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.22.4 Nanostring Technologies Inc Response to COVID-19 and Related Developments
- 7.23 Rarecells Diagnostics.
- 7.23.1 Rarecells Diagnostics. Business Overview
- 7.23.2 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Introduction
- 7.23.4 Rarecells Diagnostics. Response to COVID-19 and Related Developments
- 7.24 Vitatex Inc
- 7.24.1 Vitatex Inc Business Overview
- 7.24.2 Vitatex Inc Circulating Tumor Cell Diagnostics Quarterly Revenue, 2020
- 7.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Product Introduction
- 7.24.4 Vitatex Inc Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
- 9.1 About US
Summary:
Get latest Market Research Reports on Circulating Tumor Cell Diagnostics . Industry analysis & Market Report on Circulating Tumor Cell Diagnostics is a syndicated market report, published as Global Circulating Tumor Cell Diagnostics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Circulating Tumor Cell Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
